Growth Story Still Intact For Amicus Therapeutics Inc (FOLD)

Amicus Therapeutics Inc (FOLD) concluded trading on Wednesday at a closing price of $6.10, with 4.52 million shares of worth about $27.59 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.88% during that period and on June 04, 2025 the price saw a loss of about -2.56%. Currently the company’s common shares owned by public are about 307.92M shares, out of which, 297.28M shares are available for trading.

Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of -6.58%. Year-to-date (YTD), FOLD shares are showing a performance of -35.24% which decreased to -37.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.81 but also hit the highest price of $12.65 during that period. The average intraday trading volume for Amicus Therapeutics Inc shares is 4.14 million. The stock is currently trading -1.30% below its 20-day simple moving average (SMA20), while that difference is down -10.87% for SMA50 and it goes to -34.84% lower than SMA200.

Amicus Therapeutics Inc (NASDAQ: FOLD) currently have 307.92M outstanding shares and institutions hold larger chunk of about 99.78% of that.

The stock has a current market capitalization of $1.88B and its 3Y-monthly beta is at 0.52. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 2.47 while making debt-to-equity ratio of 2.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FOLD, volatility over the week remained 2.30% while standing at 2.77% over the month.

Stock’s fiscal year EPS is expected to rise by 51.94% while it is estimated to increase by 398.57% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 13, 2024 offering an Equal-weight rating for the stock and assigned a target price range of between $17 and $12 to it. Coverage by Jefferies stated Amicus Therapeutics Inc (FOLD) stock as a Buy in their note to investors on September 06, 2024, suggesting a price target of $18 for the stock. On May 30, 2024, Wells Fargo Initiated their recommendations, while on May 14, 2024, Guggenheim Upgrade their ratings for the stock with a price target of $13. Stock get an Overweight rating from Morgan Stanley on December 19, 2023.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.